Bi-functional shRNA (bi-shRNA), a novel RNA interference (RNAi) effector platform targeting PDX-1 utilizing a systemic DOTAP-Cholesterol delivery vehicle, was studied in three mouse models of progressive pancreatic neoplasia. 
Together, these data support the clinical development of a novel therapeutic strategy using systemic bi-shRNA lipoplexes against pancreatic neoplasia.
Pancreatic and duodenal homeobox-1 (PDX-1) is a transcription factor that plays a critical role in regulating embryologic pancreas development as well as in insulin expression and islet maintenance in the adult pancreas [1] [2] [3] [4] . PDX-1 has recently been shown to play a significant role in islet cell neoplasia and pancreatic cancer [5] [6] [7] [8] [9] [10] [11] . PDX-1 knockout is lethal in mice and mutation of PDX-1 leads to mature onset of diabetes of the young (MODY subtype IV) in mice and human patients 12, 13 . Persistent overexpression of PDX-1 leads to acinar to ductal cell metaplasia in mice 14 . Overexpression of PDX-1 in cell lines results in transformation of non-insulin-producing cells into insulin-producing cells upon GLP-1 stimulus [15] [16] [17] [18] [19] [20] . Although PDX-1 is well known as an essential regulator of many pancreatic endocrine genes (e.g., insulin [1] [2] [3] [4] , glucokinase 21 , islet amyloid polypeptide [22] [23] [24] , glucose transporter type 2 [GLUT2] 25, 26 , pancreatic polypeptide 27 and somatostatin 6, 28 ), which have critical roles in maintaining glucose homeostasis (e.g., insulin and glucokinase), the precise role of PDX-1 in pancreatic neoplasia remains unknown.
Our recent studies demonstrate that PDX-1 is a potential oncogene and a therapeutic target for pancreatic neoplasia 11, 29 . It is markedly overexpressed in pancreatic cancer 8, 10, 11, 30 and regulates proliferation and invasion of human pancreatic cancer cells in vitro and in vivo in mice 11 . PDX-1 over-expressing cells have increased tumor formation when implanted in mice 29 . We have previously demonstrated that shRNA humanPDX-1 lipoplexes effectively ablate human pancreatic cancer tumor formation in SCID mice, resulting in prolonged survival 11 .
In this study, the activity of a novel RNAi effector platform targeting PDX-1 was studied in vitro and in vivo in human and mouse cell lines as well as in mouse models of progressive pancreatic neoplasia.
Results

PDX-1 is overexpressed in human and mouse specimens of progressive pancreatic neoplasia
PDX-1 was overexpressed in 36 human pancreatic neoplasia specimens including 26 pancreatic neuroendocrine tumors (Fig. 1a-l ) and 10 nesidioblastosis specimens (Fig. 1m-o) , in mouse insulinoma (β TC-6) cells ( . Reductions in cell growth were observed at 52%, 38%, and 31% in empty vector controls at 24, 48, and 72h posttransfection, respectively, using MTS assay (Fig. 3a) and at 42%, 35%, and 42% at 12, 24, and 48h post-transfection, respectively, using BrdU incorporation assay ( Fig. 3b) at low doses (6μg or12 μg/10-cm dish) (Fig. 3f, 3g ) . These data demonstrate that species-specific PDX-1 knockdown inhibits mouse insulinoma cell and human pancreatic cancer cell proliferation via alterations in cell cycle proteins. Overall survival in both treatment groups was significantly longer than that of controls (106±7.8d vs 53±1.4d and 146±9.5d vs 53±1.4d, respectively, p<0.05 vs controls, Fig. 4f and g, sFig. 1). The difference in survival between the two treatment groups was due to intentional sacrificing of that group of mice at an earlier time point, but there is no significance (p>0.05)(sFig. 1f). These data demonstrate that PDX-1 knockdown using systemic bi-shRNA Fig. 5a and b) . Systemic glucose and insulin levels returned to baseline on day 150 after the initial treatment, although systemic insulin levels were significantly lower in the treatment group than in controls (3.1±0.2 μg/l vs 2±0.6 μg/l, p<0.05). Empty vector lipoplexes were without effect on hyperinsulinemia and hypoglycemia ( Fig. 5a and b) . Islet PDX-1 expression was reduced in a treatment-dependent manner, from 93±13.5% on day 0 to 12±2.6% on day 35 post-treatment; returning to 88±15.2% on day 150 post-treatment (Fig. 4c, top panel) . Islet PCNA expression decreased significantly from 33 ±2.8 to 6±0.6% and to 29 ±4.3% on days 0, 35 and 150d post-treatment, respectively (Fig. 5c middle panel) , which correlated to downregulation of cyclin E, cyclin D, Cdk4 and Cdk2. No effect was seen with empty vector controls (p<0.05; Fig. 5d ). Increased islet cell apoptosis also was observed (1±0.1%, 19±3.2%, 32±5.7%, 58±8.9% and 9±1.4% on days 0, 7, 14, 35 and 150 post-treatment, respectively, Fig. 5c bottom panel) . Intraperitoneal glucose tolerance tests (IPGTT) were performed on SSTR1/5 -/-mice at day 7 and 150 after the initial treatment. Fasting glucose levels in the treated group were significantly higher than that of controls (117 ± 6.8 mg/dl vs 84 ± 5.9 mg/dl, p < 0.05), whereas basal insulin levels in the treatment group were lower than those of controls (1 ± 0.1μg /l vs 2 ± 0.2 μg/l, p<0.05; Fig 5d) . Following intraperitoneal glucose injection, systemic glucose levels were significantly higher than those of controls at 60 and 240 min post-injection (234 ± 20.2 mg/dl vs 189 ± 21.0 mg/dl and 175 ± 11.3 mg/dl vs 137 ± 16.8 mg/dl, respectively p<0.05). Serum insulin levels were significantly lower than those of controls at 15 min post-injection (2 ± 0.1 μg/l vs 3 ± 0.2 μg/l) (Fig. 5e) . On post-treatment day 150, no significant difference in basal glucose levels was seen between treatment and control groups; however, basal insulin levels in the treatment group were significantly lower than in those of controls (1 ± 0.3 μg/l vs 2 ± 0.3 μg/l, p<0.05). Only the15-min time point demonstrated a significant difference in systemic glucose levels between the groups (364±60.1 vs 267.0±40.4, p<0.05). Systemic insulin levels; however, were significantly lower at the 30-and 120-min time points in the treatment group as compared to controls, (2.2± 0.3 μg/l vs 3.3 ± 0.2 μg/l and 2.5 ± 0.1μg/l vs 3.8 ± 0.3μg/l at 30 and 120 min post-injection, respectively; p<0.05) (Fig. 5g ).
These data demonstrate that three cycles of systemic shRNA (Fig 6c, 4 th panel). Marked apoptosis was seen in residual tumors (Fig. 6c, bottom panel) . Remarkably, three cycles of bishRNA humanPDX-1 lipoplexes had no effect on systemic glucose and insulin levels, underscoring the importance of the species-specific design of PDX-1 RNAi (sFig.
4).
These data demonstrate that multiple cycles of systemic shRNA humanPDX-1 lipoplexes were well tolerated and effectively reduced human pancreatic cancer tumor volume and prolonged survival in SCID mice, suggesting a clinical potential of this novel therapeutic strategy for the most aggressive form of pancreatic neoplasia.
Discussion
This study demonstrates that multiple cycles of a novel RNAi effector platform targeting PDX-1 utilizing a systemic DOTAP-Cholesterol delivery vehicle are welltolerated and effective in three mouse models of progressive pancreatic neoplasia. These findings are consistent with our previous studies that PDX-1 is a therapeutic target for pancreatic neoplasia 11, 29 . Data from the current study has demonstrated marked overexpression of PDX-1 in human specimens of pancreatic neoplasia. This, combined with our prior findings of PDX-1 expression in the most aggressive form of pancreatic neoplasia, pancreatic cancer In order to achieve multiple intravenous doses of the RNAi therapy, the liposomal delivery system used in this study was developed using 1,2-dioleoyl-3-trimethylammoniopropane (DOTAP) and cholesterol bilamellar invaginated vesicle (BIV) 34 . BIV envelope the RNAi expression vector creating a lipoplex, which achieve low morbidity, effective, and multiple sequential intravenous dose scheduling of the RNAi therapeutic 34 . The composition and structure of these lipoplexes result in an optimized ~5½ hour plasma half-life by minimizing interaction with plasma proteins and accumulation in non-target tissues; their fusogenic property avoids endocytosis, which otherwise can lead to nucleic acid degradation 35 . The safety of this lipoplex system to be administered intravenously in multiple cycles already has been demonstrated in other in vivo models to other targets 36, 37 and clinical trials 38, 39 .
In a xenograft mouse model of human pancreatic cancer, the most aggressive form of pancreatic neoplasia, our strategy of PDX-1 knockdown effectively reduced human pancreatic cancer tumor formation in SCID mice and prolonged survival 11 . It was remarkable that in the few mice with residual pancreatic cancer tumors, studies of those tumors revealed marked suppression of PDX-1 and marked enhancement of both P53 and apoptosis 90 days after therapy. This suggests that PDX-1 knockdown activated the apoptotic pathway via P53 within PANC-1 cells, similar to in vitro data seen in our previous study as well as that seen in insulinoma cell lines in this study. These findings support the concept that PDX-1 has oncogenic properties and is a potential therapeutic target for pancreatic cancer. We previously reported that 80 human pancreas tissue specimens, including liver metastases, had marked overexpression of PDX-1 8, 11, 29 . Together, these findings support the development of a phase I clinical trial using this novel RNAi platform targeting PDX-1 for treating this devastating form of pancreatic neoplasia. Interestingly, there was no adverse effect on islet PDX-1 or insulin expression, as well as insulin and glucose levels in mice, demonstrating the importance of species-specificity of the PDX-1 shRNA design.
Insulinoma is an intermediate form of pancreatic neoplasia in which tumor
formation occurs with a ratio of approximately 90% benign and 10% malignant.
The effect of PDX-1 knockdown on mouse insulinoma cells revealed 1) deactivation of an exogenous rat insulin promoter fragment; 2) decreased activation of endogenous insulin promoter resulting in inhibition of expression and secretion of insulin 3) inhibition of proliferation via alterations on cell cycle proteins, 4) prevention of lethal hypoglycemia in an insulinoma SCID mouse model and 5) temporal suppression of islet PDX-1 and insulin expression associated with mild hyperglycemia. It is to be noted that due to the rapid occurrence of malignant hypoglycemic death, there is insufficient time for implanted β TC-6 insulinoma cells to develop into measurable lesions before insulinoma-induced hypoglycemic death; therefore, there is no tumor volume to be measured in this model. However, the systemic effect of the remarkable suppression of in situ islet PDX-1 with associated suppression of insulin and PP, both known to regulate glucose homeostasis [22] [23] [24] and increased islet apoptosis, suggests the development of temporal mild hyperglycemia post-therapy is due to the effect of bi-shRNA mousePDX-1 lipoplexes on the endocrine pancreas. Combined with the finding that 36 human pancreatic neoplasia specimens had marked overexpression of PDX-1, these data suggest that our novel RNAi effector platform has clinical potential for treating pancreatic neuroendocrine tumors, which includes both malignant and benign forms of pancreatic neoplasia, as well as nesidioblastosis 40 . Furthermore, since there are no current effective treatments for the devastating hormonal symptoms associated with pancreatic neuroendocrine tumors 40 , this study suggests another potential clinical application for the novel RNAi effector platform targeting PDX-1 is the control of symptoms associated with excessive hormonal secretion associated with pancreatic neoplasia.
Our laboratory has a long history studying the role of somatostatin receptors (SSTRs) in islet physiology [41] [42] [43] [44] . We first demonstrated that mouseSSTR5 was the SSTR subtype responsible for inhibiting glucose-stimulated insulin secretion from mouse islets and then cloned the mouse SSTR5 gene. SSTR5 were fasted overnight before collection of blood samples as T0. Grouped mice were then given 1.2g glucose/kg body weight via ip injection followed by collection of blood samples at 15, 30, 60, and 120 min after injection of glucose. Glucose and insulin levels were measured as described above.
Necropsy, tissue collection, immunohistochemistry and TUNEL assay
Pancreatic and tumor tissue sampels were obtained on days 0, 7, 21, 35, and end time after initial gene delivery. IHC was performed as described previously.
Anti-PDX-1, insulin, PP, cyclin E, p27, Cdk4 or PCNA antibodies was applied to slides with 1:100 dilution followed by overnight incubation at 4°C. Slides were incubated with Cy3 or FITC-conjugated anti-rabbit, goat, or mouse secondary antibody depending on derivation of primary antibodies for one hour, and mounted with cover slides. TUNEL assay (FragEL 
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